09 February 2026

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Change of Joint Broker

Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces the appointment of Singer Capital Markets as Joint Corporate Broker with immediate effect following the transfer of Dowgate Capital's corporate broking, advisory and research team to Singer Capital Markets.

For further information, please contact: 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts.  The Company has identified four market sectors:

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·      Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,

·      Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com